New hepatitis C treatments to be listed on the Pharmaceutical Benefits Scheme

Tracy Parish

19 February, 2013

The Federal Government has announced it will provide $220 million over five years to subsidise two new hepatitis C treatments, boceprevir and telaprevir.

About half of those with hepatitis C in Australia have genotype 1. Boceprevir and telaprevir, known as direct acting antivirals, have been shown to cure up to 75 percent of people with chronic hepatitis C genotype 1.

With the improved accessibility of these new drugs, there is likely to be far fewer cases of liver cancer resulting from chronic hepatitis C.

These new antiviral therapies have the potential to improve tolerability and reduce the duration of treatment, in combination with existing therapies.

Professor Margaret Hellard, Head of Burnet’s Centre for Population Health, said it was an important step forward.

“This is good news for people living with hepatitis C in Australia who have been waiting for almost a year for the release of these two medications.”

“For many people in Australia infected with hepatitis C genotype 1, the existing medications have not been effective in treating their infection.

“These new medications increase the chance of treatment successfully clearing the infection and improving people’s long term health.”

For more information visit CREIDU’s website at

Staff Member



Health Issue

Contact Details

For more information in relation to this news article, please contact:

Professor Margaret Hellard AM

Deputy Director (Programs); Adjunct Professor, Monash University, DEPM.




Subscribe to News

Subscribe to receive our latest news: